ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.
In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.
Meta-analysis suggests that calcium channel blockers can be effective in preventing peripheral arterial disease in patients with hypertension.
The dapagliflozin treatment arm experienced significant body weight reductions, lower body mass index scores, lower systolic blood pressure, and an increase in levels of hemoglobin (P<.05).
Following the 2007 American Heart Association (AHA) update of recommendations for antibiotic prophylaxis (AP) to prevent infective endocarditis (IE), there has been a decrease in AP and an increase in IE incidence for high-risk individuals.
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
The clinical trial is based on research from a number of laboratories, including that of Harvard-affiliated Brigham and Women's Hospital researcher Piero Anversa, MD.
The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non-fatal stroke, CV death) in patients treated with liraglutide 1.8mg once daily or placebo.
The researchers found that VTE events occurred in 1.38% of patients, including 4.79% of those who received no pharmacologic prophylaxis, 1.16% treated with aspirin alone, 1.42% of those treated with anticoagulation alone, and 1.31% prescribed both aspirin and anticoagulation.
The FDA approval was supported by data from the Phase 3 COMPASS trial (N=27,395) which evaluated Xarelto with or without aspirin for the long-term prevention of major adverse CV events (including MI, stroke, CV death) in patients with chronic CAD or PAD.
For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.
Dr C was determined to fight this case, and his defense attorney was supportive after looking at the detailed notes and documented calls to the patient which were never returned.
Although discontinuation of the medication resolved the patient's symptoms initially, spontaneous bruising recurred and progressed over several weeks, prompting the patient to seek medical attention for persistent bruising in her upper extremities.
At a median follow-up of 3.3 years, rates of symptomatic venous thromboembolism or death due to thromboembolism were similar for medically ill patients treated with rivaroxaban or placebo for 45 days following hospital discharge.
The Eluvia stent is designed to release paclitaxel for a 1-year time frame to prevent tissue regrowth that might otherwise block the stented artery.
The researchers found that a composite outcome of symptomatic venous thromboembolism or death due to venous thromboembolism occurred in 0.83% of patients in the rivaroxaban group and in 1.10% in the placebo group (hazard ratio, 0.76; 95% confidence interval, 0.52 to 1.09; P=0.14).
The intent of the document is to help reduce heparin product overdose errors caused by misinterpretation of the drug strength displayed in the labeling.
The Agency reviewed real-world data from 80 patients who received the PK Papyrus Stents, finding that the stents were delivered successfully to the perforation site in 95% of patients with successful seals seen in 73 patients 91.3% of patients.
The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months.
To investigate the cardiovascular risks associated with diclofenac, researchers conducted a series of cohort studies mimicking the design criteria of a clinical trial.
Buerger's disease is a nonatherosclerotic, segmental inflammatory disorder that affects small and medium vessels of the upper and lower extremities and is strongly associated with tobacco exposure.
In this randomized trial of patients with aphasia, use of anodal transcranial direct current stimulation (A-tDCS) demonstrated improved object naming compared to sham procedure.
The new analysis included 19,134 of these patients and showed that there were 19% fewer deaths in patients initiated on NOACs compared to VKAs at the time of AF diagnosis.
For this double-blind, placebo-controlled study, researchers selected male patients ≥55 years and female patients ≥60 years with average cardiovascular risk and assigned them to enteric-coated aspirin 100mg (N=6270) or placebo (N=6276) once daily; the median follow-up time was 60 months.
In the CAMELLIA-TIMI 61 study, 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors were randomized to receive either lorcaserin 10mg twice daily or placebo.
Compared with women who had never breastfed, those who reported ever breastfeeding had a significantly lower risk of stroke after adjustment for non-modifiable potential confounders (adjusted hazard ratio, 0.77).
Treatment with xenon may improve functional outcomes and reduce mortality in cardiac arrest survivors.